Stock Price & Analysis

Based on the provided data and current market conditions, here's a comprehensive analysis of PHG stock:

Technical Analysis

The stock is currently showing mixed technical signals:

• RSI-14 at 62.52 indicates moderately overbought conditions
• MACD is slightly bullish with a positive reading of 0.55
• Stock is trading above both its 5-day (28.11) and 20-day (27.31) moving averages
• Current price of 28.19 is testing the upper Bollinger Band (29.34), suggesting potential resistance

Fundamental Analysis

Key valuation metrics show:

• P/S ratio: 0.74x
• P/B ratio: 0.97x
• Dividend yield: 5.96%
• EV/EBITDA: 7.51x

Business Segments

Revenue distribution shows:

• Diagnosis & Treatment: 51.43%
• Connected Care: 24.70%
• Personal Health: 20.34%
• Other: 3.53%

Recent Developments A significant positive development is Philips' successful deployment of nationwide acute stroke care upgrade in Ukraine. The company is installing 25 Azurion interventional suites and providing comprehensive clinical training, which demonstrates its commitment to expanding healthcare infrastructure globally.

Recommendation SELL - While Philips shows some positive developments in its healthcare initiatives, several factors suggest taking profits at current levels:

1. Technical indicators show overbought conditions
2. The stock is testing resistance levels
3. Historical analyst ratings trend has been predominantly downward
4. Current price is above both short-term moving averages, suggesting potential pullback

Based on the provided data and market context, let me analyze PHG's price prediction for 2025:

Technical Analysis

The current technical indicators show:

• RSI-14 at 62.52 indicates moderately bullish momentum
• MACD is positive with bullish divergence (MACD: 0.55, Signal: 0.46)
• Stock trading above key moving averages (SMA200: $27.71, SMA50: $26.33)
• Strong Stochastic readings (K:89.86, D:90.83) suggesting overbought conditions

Price Target Analysis

Based on Fibonacci levels:

• Support levels: $26.87 (S1), $26.37 (S2), $25.58 (S3)
• Resistance levels: $28.45 (R1), $28.95 (R2), $29.74 (R3)
• Pivot point: $27.66

Fundamental Factors

Key metrics:

• EV/EBITDA: 7.38 (2023/FY)
• Price/Sales: 1.09 (2023/FY)
• Price/Book: 1.59 (2023/FY)

2025 Price Prediction

Based on technical and fundamental analysis, PHG stock is likely to trade in the range of $28-31 by end of 2025, with a base case target of $29.50. This prediction is supported by:

1. Strong technical momentum above key moving averages
2. Reasonable valuation metrics suggesting room for multiple expansion
3. Fibonacci resistance levels indicating potential upside targets

The S1 support level for PHG Stock is $25.16 ,The R1 resistant level for PHG Stock is $28.41.

As of the end of day on 2025-02-21, the price of PHG Stock was $25.26.

The target price for PHG Stock according to analyst rating is 28.80, with the highest price target at 33.00 and the lowest at 26.40. Analysts have a Moderate Buy rating on PHG Stock overall.

The market cap of PHG is $24.0B.

Based on the financial data and market analysis, PHG shows mixed valuation signals. The company's EV/EBITDA ratio of 7.38 is relatively reasonable, but its negative earnings make traditional P/E analysis challenging. The gross margin improved from 40.57% to 44.16% year-over-year, showing operational efficiency gains. Net losses significantly narrowed from -$1.69B to -$503M, indicating progress toward profitability. The current price-to-sales ratio of 1.09 suggests moderate valuation compared to historical levels. The debt-to-equity ratio increased slightly to 60.46%, which warrants monitoring but isn't alarming.

Koninklijke Philips NV is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.

Based on the provided data, I'll analyze PHG's price prediction for 2030:

Technical Analysis

• Current price: $28.19 (as of Feb 14, 2025)
• The stock shows a strong support level around $25-26 range
• RSI(14) at 62.52 indicates moderate bullish momentum without being overbought
• MACD is positive with bullish divergence (MACD: 0.55, Signal: 0.46)

Fundamental Factors

• Healthcare technology sector transformation
• Recent strategic initiatives:
  • Major stroke care upgrade program in Ukraine
  • Partnership with World Stroke Organization for global healthcare infrastructure
  • Focus on diagnostic imaging and image-guided therapy

Growth Catalysts

• Expanding presence in emerging markets
• Investment in AI and digital health solutions
• Strong position in diagnostic imaging and monitoring solutions

Price Target 2030 Analysis

Based on:

1. Historical growth patterns
2. Industry transformation
3. Strategic positioning
4. Technical indicators

Price prediction for 2030: $42-45 range

Reasoning:

• Compound annual growth rate (CAGR) projection: ~8-9%
• Healthcare technology sector expansion
• Market leadership in diagnostic imaging
• Strong global partnerships and infrastructure development

Risk Factors

• Market competition
• Regulatory changes
• Economic uncertainties
• Technology disruption

PHG has a total of 69656 employees.